Research.Patient.info
Higher-risk Myelodysplastic Syndrome research hub
2 indexed studies · 2 currently recruiting
- recruitingPHASE3
Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).
This study is looking into a new combination treatment for a type of blood cancer called higher-risk myelodysplastic syndrome (MDS). It's testing if adding a drug called lisaftoclax to a standard treatment, azacitidine, helps people live longer. Half the participants will get the new drug, and half a dummy drug.
United States · Australia · Belgium - recruitingPHASE1, PHASE2
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
This study is testing a new drug, CCS1477 (also called inobrodib), for people with certain blood cancers like lymphoma, myeloma, or leukaemia. It aims to see if the drug is safe, well-tolerated, and how it works in the body.
United States · France · Spain